Press Release: Breakthrough Therapies Available for Treatment-Resistant DepressionBy Dallas CADT | Posted on March 10, 2021 | News
The Dallas Center for Advanced Depression Treatments (CADT), a certified treatment center for major depressive disorders (MDDs), is partnering with community psychiatric providers in DFW to administer next-generation therapies to patients with treatment-resistant depression. Dallas CADT was the first certified treatment center for FDA-approved SPRAVATO© (esketamine) nasal spray in the Metroplex. And it is one of the first facilities in the area to administer FDA-approved BrainsWay Deep TMS for depression, OCD and smoking cessation.
The delivery of treatment-resistant depression therapies is not painful or disruptive, but requires an environment where patients can safely receive treatment under the observation of medical staff certified in psychiatry and mental health. Patients who qualify for these treatments have a type of depression that has failed to respond to at least two previous medications.
“I am confident when I refer patients to the Dallas CADT that they will receive individualized care in a comfortable and professional environment,” said Stephen Vobach, MD, a Dallas psychiatrist who has referred patients to the center for treatment.
Among the novel interventions offered by Dallas CADT are:
- SPRAVATO© (esketamine) – the intranasal spray targets the N-methyl-D-aspartate (NMDA) receptor. Unlike traditional antidepressants, which can take weeks or months for their effects to be felt, esketamine works within hours or days.
- BrainsWay dTMS – deep TMS enables non-invasive activation of deeper and broader brain structures than can be achieved using traditional figure-8 coil TMS systems. The response rate for BrainsWay dTMS plus medication is 67% vs. 44% for standard rTMS plus medication.
- Intranasal ketamine – a less invasive, affordable alternative to IV ketamine used to treat some depressive illnesses, including Bipolar Disorder and PTSD.
- Abilify Maintena – a once-monthly injection treatment approved by the FDA for bipolar 1 disorder maintenance. This eliminates the need for daily oral medications in appropriate patients.
About Dallas CADT
Located along the Dallas North Tollway, Dallas CADT serves the entire DFW Metroplex. Welcoming referrals for patients suffering from treatment-resistant depression, the center is led by Marty N. Bennett, MD, a board-certified psychiatrist and former faculty member at UT Southwestern Medical School